Biological
KN035
KN035 is a biological therapy with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
50%
Ph phase_2
3
50%
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(3)
Other(2)
Detailed Status
Completed3
unknown2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (50.0%)
Phase 23 (50.0%)
Trials by Status
recruiting117%
completed350%
unknown233%
Recent Activity
1 active trials
Showing 5 of 6
recruitingphase_2
KN035 for dMMR/MSI-H Advanced Solid Tumors
NCT03667170
completedphase_1
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
NCT03101488
completedphase_1
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03248843
completedphase_1
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
NCT02827968
unknownphase_2
KN035 in Patients With Advanced Multiple Primary Tumors
NCT04182789
Clinical Trials (6)
Showing 6 of 6 trials
NCT03667170Phase 2
KN035 for dMMR/MSI-H Advanced Solid Tumors
NCT03101488Phase 1
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
NCT03248843Phase 1
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
NCT02827968Phase 1
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
NCT04182789Phase 2
KN035 in Patients With Advanced Multiple Primary Tumors
NCT04034823Phase 2
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6